https://rijournals.com/scientific-and-experimental-sciences/

RESEARCH INVENTION JOURNAL OF SCIENTIFIC AND EXPERIMENTAL SCIENCES 5(2):8-11, 2025

©RIJSES Publications

ONLINE ISSN: 1115-618X

PRINT ISSN: 1597-2917

https://doi.org/10.59298/RIJSES/2025/52811

The Efficacy of Monoclonal Antibodies for Prophylaxis and Treatment of Malaria: A Narrative Review of Clinical Trials

Chelimo Faith Rebecca

Department of Clinical Medicine and Dentistry Kampala International University Uganda
Email: rebecca.chelimo@studwc.kiu.ac.ug

ABSTRACT

Malaria remains a major global health challenge, particularly in endemic regions where conventional control measures face limitations due to drug resistance and logistical barriers. Monoclonal antibodies (mAbs) have emerged as a promising strategy for both malaria prophylaxis and treatment, leveraging their high specificity and prolonged half-life to provide durable protection against Plasmodium infection. This narrative review synthesized findings from clinical trials investigating the efficacy of monoclonal antibodies in preventing and treating malaria. A comprehensive literature search was conducted to analyze the mechanisms of action, pharmacokinetic properties, clinical efficacy, and safety profiles of leading mAb candidates. Prophylactic mAbs, such as CIS43LS and L9LS, have demonstrated significant protection in controlled human malaria infection studies, with extended half-lives facilitating long-term prevention. Therapeutic mAbs targeting blood-stage parasites show potential for reducing parasite burden, particularly in drug-resistant cases. Despite their promise, challenges such as high production costs, potential resistance development, and integration into existing malaria control programs must be addressed. Future research should focus on large-scale field trials, cost-effective manufacturing, and synergistic implementation with vaccines and vector control measures. Monoclonal antibodies could play a pivotal role in malaria eradication efforts, provided that their accessibility and affordability challenges are adequately resolved.

Keywords: Monoclonal Antibodies, Malaria Prophylaxis, Malaria Treatment, Clinical Trials, Plasmodium Infection.

INTRODUCTION

Malaria remains a significant global health burden, particularly in tropical and subtropical regions where Plasmodium species are endemic [1–3]. Despite advancements in vector control and chemoprophylaxis, the disease continues to pose substantial morbidity and mortality risks, particularly among vulnerable populations such as children and pregnant women. The increasing emergence of drug-resistant Plasmodium strains has necessitated the exploration of novel therapeutic and prophylactic strategies [4]. One promising approach is the use of monoclonal antibodies (mAbs), which offer targeted and long-lasting protection against malaria by neutralizing key parasite antigens and inhibiting parasite invasion or replication.

Monoclonal antibodies have shown considerable potential as both prophylactic and therapeutic agents against malaria, with several candidates advancing through clinical trials [5, 6]. These antibodies are designed to provide passive immunity by targeting crucial parasite proteins such as circumsporozoite protein (CSP) or merozoite surface proteins. Advances in biotechnology have enabled the development of humanized and fully human monoclonal antibodies with extended half-lives, enhancing their feasibility for malaria prevention and treatment. Unlike conventional antimalarial drugs, which may lead to resistance over time, monoclonal antibodies offer a distinct mechanism of action that could complement existing malaria control measures. This narrative review examines the efficacy of monoclonal antibodies in malaria prophylaxis and treatment, focusing on evidence from clinical trials. It explores their mechanisms of action, pharmacokinetic properties, clinical efficacy, safety profiles, and potential for integration into malaria elimination programs. Furthermore, the review highlights current challenges and future research directions necessary for optimizing monoclonal antibody-based interventions against malaria.

Mechanisms of Action of Monoclonal Antibodies in Malaria

Monoclonal antibodies exert their antimalarial effects by targeting specific proteins involved in the parasite's life cycle [7]. The circumsporozoite protein (CSP), a surface protein of Plasmodium falciparum sporozoites, has been a primary target for malaria mAbs [8]. CSP-targeting antibodies, such as CIS43LS and L9LS, block sporozoite invasion of hepatocytes, thereby preventing liver-stage infection. Other mAbs have been developed against blood-stage merozoites, aiming to inhibit red blood cell invasion and subsequent parasite replication. One of the key advantages of monoclonal antibodies over traditional antimalarial drugs is their high specificity, reducing off-target effects and minimizing toxicity [9]. Additionally, engineered mAbs with Fc region modifications enhance their half-life, ensuring prolonged protection with a single administration. These attributes make monoclonal antibodies attractive candidates for malaria prophylaxis, particularly in regions where seasonal malaria transmission necessitates long-lasting protective measures.

Clinical Efficacy of Monoclonal Antibodies in Malaria Prophylaxis

Several clinical trials have investigated the efficacy of monoclonal antibodies for malaria prevention. CIS43LS, a potent CSP-targeting antibody, has demonstrated high levels of protection in controlled human malaria infection (CHMI) studies [10]. In phase 1 trials, CIS43LS provided sustained protection against P. falciparum challenge, with an extended half-life allowing for durable prophylactic coverage. Another promising candidate, L9LS, has shown superior neutralization capacity and extended durability compared to its predecessors, making it a viable candidate for malaria prophylaxis. Field studies are essential to validate the real-world effectiveness of monoclonal antibodies in endemic settings. Preliminary data suggest that a single-dose administration of these antibodies can confer several months of protection, offering a strategic advantage for seasonal malaria chemoprevention (SMC) programs. Future trials must assess their long-term protective efficacy, optimal dosing regimens, and potential for integration with existing malaria control interventions.

Monoclonal Antibodies in Malaria Treatment

While most monoclonal antibody research has focused on prophylaxis, there is increasing interest in their therapeutic potential. Blood-stage-targeting mAbs aim to reduce parasite burden in infected individuals, offering an alternative to conventional antimalarial drugs [11]. Clinical trials investigating mAbs against merozoite antigens, such as RH5 and AMA1, have shown promising reductions in parasite replication. These antibodies could be used as adjunctive therapy to enhance treatment efficacy, particularly in cases of drug-resistant malaria. Another potential therapeutic application of monoclonal antibodies is their use in severe malaria cases. Patients with cerebral or complicated malaria often experience high parasite loads, leading to systemic inflammation and organ dysfunction. Passive immunotherapy with monoclonal antibodies may provide a rapid parasite clearance mechanism, improving clinical outcomes [12, 13]. However, further studies are needed to establish their efficacy and safety in critically ill patients.

Safety and Pharmacokinetic Considerations

Safety is a crucial factor in the clinical development of monoclonal antibodies for malaria. Early-phase trials have reported minimal adverse effects, with most mAbs exhibiting favorable tolerability profiles [14]. Unlike small-molecule antimalarial drugs, monoclonal antibodies are less likely to cause hepatotoxicity or neurotoxicity, given their targeted mode of action. However, immune-mediated adverse reactions, such as hypersensitivity responses, must be carefully monitored in clinical studies. Pharmacokinetically, monoclonal antibodies benefit from extended half-lives, enabling prolonged protection with a single dose [15]. Fc-engineered mAbs can persist in circulation for months, reducing the frequency of administration and enhancing compliance in malaria-endemic regions. Future research should focus on optimizing dosing strategies to maximize efficacy while minimizing potential risks associated with immunogenicity and resistance development.

Challenges and Future Directions

Despite their promise, several challenges must be addressed before monoclonal antibodies can be widely implemented for malaria prevention and treatment. One major limitation is the high cost of production, which may hinder accessibility in low-resource settings where malaria burden is highest [16, 17, 18, 19]. Advances in manufacturing technologies and economies of scale will be crucial in making monoclonal antibodies cost-effective for large-scale deployment. Another challenge is the potential for resistance development. While monoclonal antibodies have a different mechanism of action compared to traditional antimalarial drugs, selective pressure on parasite populations could lead to antigenic variations that reduce mAb efficacy [17, 20, 21, 22, 23]. Continuous surveillance and adaptive strategies will be essential to mitigate this risk. Moreover, integrating monoclonal antibodies into existing malaria control programs requires careful consideration of logistical and operational factors [18-23]. Coordination with malaria vaccination efforts, vector control measures, and chemoprophylaxis programs will be necessary to maximize their impact. Large-scale field trials are needed to generate robust data on their effectiveness in diverse epidemiological settings.

CONCLUSION

Monoclonal antibodies represent a promising frontier in malaria prophylaxis and treatment, offering targeted and long-lasting protection against Plasmodium infection. Clinical trials have demonstrated their efficacy in preventing malaria through CSP-targeting antibodies, while therapeutic mAbs against blood-stage parasites show potential for reducing disease severity. Their extended half-lives and favorable safety profiles make them viable candidates for integration into malaria control strategies. However, challenges related to cost, accessibility, and resistance development must be addressed to ensure their successful implementation. Future research should focus on optimizing their clinical use, scaling up production, and integrating them into comprehensive malaria eradication programs. With continued advancements in monoclonal antibody technology, these biologics may play a pivotal role in achieving global malaria elimination goals.

REFERENCES

1. Milner, D.A., Vareta, J., Valim, C., Montgomery, J., Daniels, R.F., Volkman, S.K., Neafsey, D.E., Park, D.J., Schaffner, S.F., Mahesh, N.C., Barnes, K.G., Rosen, D.M., Lukens, A.K., Van Tyne, D., Wiegand, R.C., Sabeti, P.C., Seydel, K.B., Glover, S.J., Kamiza, S., Molyneux, M.E., Taylor, T.E., Wirth, D.F.: Human cerebral malaria and Plasmodium falciparum genotypes in Malawi. Malar J. 11, 35 (2012). https://doi.org/10.1186/1475-2875-11-35
2. Alum, E.U., Tufail, T., Agu, P.C., Akinloye, D.I., Obaroh, I.O.: Malaria pervasiveness in Sub-Saharan Africa: Overcoming the scuffle. Medicine. 103, e40241 (2024). https://doi.org/10.1097/MD.0000000000040241
3. Ogbonnia Egwu, C., Aloke, C., Chukwu, J., Agwu, A., Alum, E., Tsamesidis, I., M Aja, P., E Offor, C., Ajuka Obasi, N.: A world free of malaria: It is time for Africa to actively champion and take leadership of elimination and eradication strategies. Afr Health Sci. 22, 627–640 (2022). https://doi.org/10.4314/ahs.v22i4.68
4. Adigo Shibeshi, M., Demelash Kifle, Z., Asrade Atnafie, S., Adigo Shibeshi Zemene Demelash Kifle Seyfe Asrade Atnafie, M.: Antimalarial drug resistance and novel targets for antimalarial drug discovery. Infect Drug Resist. 13, 4047–4060 (2020). https://doi.org/10.2147/IDR.S279433
5. Wang, L.T., Idris, A.H., Kisalu, N.K., Crompton, P.D., Seder, R.A.: Monoclonal antibodies to the circumsporozoite proteins as an emerging tool for malaria prevention. Nature Immunology 2024 25:9. 25, 1530–1545 (2024). https://doi.org/10.1038/s41590-024-01938-2
6. Miura, K., Flores-Garcia, Y., Long, C.A., Zavala, F.: Vaccines and monoclonal antibodies: new tools for malaria control. Clin Microbiol Rev. 37, (2024). https://doi.org/10.1128/CMR.00071-23/ASSET/842E9625-47B3-4C58-9C22-2A7E5A10DA6F/ASSETS/IMAGES/LARGE/CMR.00071-23.F004.JPG
7. Aleshnick, M., Florez-Cuadros, M., Martinson, T., Wilder, B.K.: Monoclonal antibodies for malaria prevention. Molecular Therapy. 30, 1810–1821 (2022). https://doi.org/10.1016/J.YMTHE.2022.04.001
8. Livingstone, M.C., Bitzer, A.A., Giri, A., Luo, K., Sankhala, R.S., Choe, M., Zou, X., Dennison, S.M., Li, Y., Washington, W., Ngauy, V., Tomaras, G.D., Joyce, M.G., Batchelor, A.H., Dutta, S.: In vitro and in vivo inhibition of malaria parasite infection by monoclonal antibodies against Plasmodium falciparum circumsporozoite protein (CSP). Scientific Reports 2021 11:1. 11, 1–15 (2021). https://doi.org/10.1038/s41598-021-84622-x
9. Batista, F.A., Gyau, B., Vilacha, J.F., Bosch, S.S., Lunev, S., Wrenger, C., Groves, M.R.: New directions in antimalarial target validation. Expert Opin Drug Discov. 15, 189–202 (2020). https://doi.org/10.1080/17460441.2020.1691996
10. Lyke, K.E., Berry, A.A., Mason, K., Idris, A.A., O'Callahan, M., Happe, M., Strom, L., Berkowitz, N.M., Guech, M., Hu, Z., Castro, M., Basappa, M., Wang, L., Naqvi, M., Low, K., Holman, L.A., Mendoza, F., Gordon, I.J., Plummer, S.H., Trofymenko, O., Strauss, K.S., Joshi, S., Shrestha, B., Adams, M., Campos Chagas, A., Murphy, J.R., Stein, J.A., Hickman, S.P., McDougal, A.J., Lin, B., Narparla, S., Vazquez, S., Serebryannyy, L., McDermott, A., Gaudinski, M.R., Capparelli, E. V., Coates, E.E., Wu, R.L., Ledgerwood, J.E., Dropulic, L.K., Seder, R.A., Team, V. 612 P.C.S.: Optimization of the CIS43LS Malarial Monoclonal Antibody and Protection Against Malaria. SSRN Electronic Journal. (2022). https://doi.org/10.2139/SSRN.4240619
11. Burgert, L.: Modelling to guide the development of pharmaceutical interventions against malaria. (2022). https://doi.org/10.5451/UNIBAS-EP91671

12. Boniche, C., Rossi, S.A., Kischkel, B., Barbalho, F.V., Moura, Á.N.D., Nosanchuk, J.D., Travassos, L.R., Taborda, C.P.: Immunotherapy against Systemic Fungal Infections Based on Monoclonal Antibodies. Journal of Fungi 2020, Vol. 6, Page 31. 6, 31 (2020). https://doi.org/10.3390/JOF6010031
13. Chandley, P., Ranjan, R., Kumar, S., Rohatgi, S.: Host-parasite interactions during Plasmodium infection: Implications for immunotherapies. Front Immunol. 13, 1091961 (2023). https://doi.org/10.3389/FIMMU.2022.1091961/PDF
14. Lee, D.H.: Update of early phase clinical trials in cancer immunotherapy. BMB Rep. 54, 70 (2021). https://doi.org/10.5483/BMBREP.2021.54.1.242
15. Liu, L.: Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins. Protein Cell. 9, 15–32 (2018). https://doi.org/10.1007/S13238-017-0408-4
16. Sibomana, O., Bukuru, J., Saka, S.A., Uwizeyimana, M.G., Kihunyu, A.M., Obianke, A., Damilare, S.O., Bueh, L.T., Agbelemoge, B. of G., Oveh, R.O.: Routine malaria vaccination in Africa: a step toward malaria eradication? Malaria Journal. 24, 1–9 (2025). https://doi.org/10.1186/S12936-024-05235-Z/FIGURES/1
17. Naung, M.T., Martin, E., Munro, J., Mehra, S., Guy, A.J., Laman, M., Harrison, G.L.A., Tavul, L., Hetzel, M., Kwiatkowski, D., Mueller, I., Bahlo, M., Barry, A.E.: Global diversity and balancing selection of 23 leading Plasmodium falciparum candidate vaccine antigens. PLoS Comput Biol. 18, e1009801 (2022). https://doi.org/10.1371/JOURNAL.PCBI.1009801
18. Obeagu, E. I., Alum, E. U. and Ugwu, O. P. C. Hepcidin's Antimalarial Arsenal: Safeguarding the Host. NEWPORT INTERNATIONAL JOURNAL OF PUBLIC HEALTH AND PHARMACY. 2023; 4(2):1-8. https://doi.org/10.59298/NIJPP/2023/10.1.1100
19. Okechukwu PC Ugwu, Okwesili FC Nwodo, Parker E Joshua, Christian E Odo, Abubakar Bawa, EC Ossai, CC Adonu Anti-malaria and hematological analyses of ethanol leaf extract of Moringa oleifera on malaria infected mice International Journal of Pharmacy and Biological Science 2013. 3(1) 360-371.
20. Okechukwu PC Ugwu, OFC Nwodo, PE Joshua, CE Odo, EC Ossai, B Aburbakar.Ameliorative effects of ethanol leaf extract of Moringa oleifera on the liver and kidney markers of malaria infected mice. 2013.2(2) 43-52.
21. Okechukwu PC Ugwu, Okwesili FC Nwodo, Parker E Joshua, Christian E Odo, Emmanuel C Ossai The effect of ethanol leaf extract of Moringa oleifera on the lipid profile of malaria infected mice Journal of applied science 2013. 4(1) 1324-1332.
22. Enechi OC, CC Okpe, GN Ibe, KO Omeje, PC Ugwu Okechukwu. Effect of Buchholzia coriacea methanol extract on haematological indices and liver function parameters in Plasmodium berghei-infected mice Global Veterinaria 2016. 16(1) 57-66.
23. Okechukwu Paul-Chima Ugwu Anti-Malaria Effect of Ethanol Extract of Moringa Oleifera (Agbaji) Leaves on Malaria Induced Mice. University of Nigeria Nsukka, 2011. 39.

CITE AS: Chelimo Faith Rebecca (2025). The Efficacy of Monoclonal Antibodies for Prophylaxis and Treatment of Malaria: A Narrative Review of Clinical Trials. RESEARCH INVENTION JOURNAL OF SCIENTIFIC AND EXPERIMENTAL SCIENCES 5(2):8-11.
https://doi.org/10.59298/RIJSES/2025/52811